{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:00:50Z","timestamp":1758042050386,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ajo.2022.11.010","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T18:21:46Z","timestamp":1668190906000},"page":"70-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparison of Uveitis Incidence by Medication in Juvenile Idiopathic Arthritis and Implications for Screening"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2299-7764","authenticated-orcid":false,"given":"Henry S.","family":"Bison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Janetos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans M.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0174-1428","authenticated-orcid":false,"given":"David L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8961-6343","authenticated-orcid":false,"given":"Brenda L.","family":"Bohnsack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2022.11.010_bib0001","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2022.11.010_bib0002","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/rheumatology\/kez449","article-title":"The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data","volume":"59","author":"Davies","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.ajo.2022.11.010_bib0003","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/art.40544","article-title":"Risk factors and biomarkers for the occurrence of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis study","volume":"70","author":"Tappeiner","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2022.11.010_bib0004","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acr.23871","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis","volume":"71","author":"ST","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ajo.2022.11.010_bib0005","unstructured":"Enjg J. (2022, Feb). ROC analysis: web-based calculator for ROC curves. www.rad.jhmi.edu\/jeng\/javarad\/roc\/JROCFITi.html."},{"issue":"16","key":"10.1016\/j.ajo.2022.11.010_bib0006","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group","volume":"326","author":"Giannini","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2022.11.010_bib0007","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13075-019-1950-7","article-title":"Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era","volume":"21","author":"Giancane","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.ajo.2022.11.010_bib0008","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1093\/rheumatology\/keaa733","article-title":"A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis","volume":"60","author":"van Straalen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ajo.2022.11.010_bib0009","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.27416","article-title":"Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis","volume":"62","author":"Saurenmann","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ajo.2022.11.010_bib0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12969-017-0195-8","article-title":"Incidence and predictors of uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study","volume":"15","author":"Nordal","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"10.1016\/j.ajo.2022.11.010_bib0011","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3899\/jrheum.131494","article-title":"Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis","volume":"41","author":"Calandra","year":"2014","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2022.11.010_bib0012","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ajo.2022.11.010_bib0013","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.ajo.2022.11.010_bib0014","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2006.08.044","article-title":"Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents","volume":"149","author":"Saurenmann","year":"2006","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.ajo.2022.11.010_bib0015","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.22613","article-title":"Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the Biologics in Pediatric Rheumatology Registry","volume":"67","author":"Foeldvari","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.ajo.2022.11.010_bib0016","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ajo.2022.11.010_bib0017","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.ajo.2022.11.010_bib0018","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ajo.2022.11.010_bib0019","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.11.010_bib0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/CEOR.S197117","article-title":"Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis","volume":"11","author":"Marshall","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.ajo.2022.11.010_bib0021","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422004330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422004330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:51:14Z","timestamp":1757598674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939422004330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":21,"alternative-id":["S0002939422004330"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2022.11.010","relation":{},"ISSN":["0002-9394"],"issn-type":[{"type":"print","value":"0002-9394"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Uveitis Incidence by Medication in Juvenile Idiopathic Arthritis and Implications for Screening","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2022.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}